FN1 and non-small cell lung carcinoma: In patients with NSCLC treated with anlotinib, detection of plasma FN1 levels has potential predictive value for anlotinib efficacy in both the discovery and validation cohorts, suggesting that plasma FN1 levels could be used as a biomarker for anlotinib stratification in NSCLC patients [13].